Abstract
Fondaparinux is the first drug from the pentassaccharide factor X inhibitor class of anticoagulants to be approved for clinical use. It has been shown to be effective in the prevention of deep vein thrombosis in patients undergoing major orthopaedic surgery of the lower limbs. The drug is also being evaluated for use in the acute coronary syndromes and established thromoboembolic events. The pharmacology of fondaparinux is discussed in this review, as well as the major clinical trials involving this drug. Arguments for (and against) the use of this drug are also summarised.
Keywords: fondaparinux, factor x inhibitors, deep vein thrombosis prophylaxis, acute coronary syndrome, pentassacharide
Current Pharmaceutical Design
Title: Fondaparinux
Volume: 11 Issue: 4
Author(s): Kiat T. Tan and Gregory Y.H. Lip
Affiliation:
Keywords: fondaparinux, factor x inhibitors, deep vein thrombosis prophylaxis, acute coronary syndrome, pentassacharide
Abstract: Fondaparinux is the first drug from the pentassaccharide factor X inhibitor class of anticoagulants to be approved for clinical use. It has been shown to be effective in the prevention of deep vein thrombosis in patients undergoing major orthopaedic surgery of the lower limbs. The drug is also being evaluated for use in the acute coronary syndromes and established thromoboembolic events. The pharmacology of fondaparinux is discussed in this review, as well as the major clinical trials involving this drug. Arguments for (and against) the use of this drug are also summarised.
Export Options
About this article
Cite this article as:
Tan T. Kiat and Lip Y.H. Gregory, Fondaparinux, Current Pharmaceutical Design 2005; 11 (4) . https://dx.doi.org/10.2174/1381612053382089
DOI https://dx.doi.org/10.2174/1381612053382089 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Transcutaneous Treatments of Hepatocellular Carcinoma in Patients with Cirrhosis: Present Status and Future Developments
Current Pharmaceutical Design Ultrasound-Assisted Catheter-Directed Thrombolysis in High-Risk and Intermediate-High-Risk Pulmonary Embolism: A Meta-Analysis
Current Vascular Pharmacology The Renin-Angiotensin Systems: Evolving Pharmacological Perspectives for Cerebroprotection
Current Pharmaceutical Design Malignancy and Radiation-Induced Cardiotoxicity
Cardiovascular & Hematological Disorders-Drug Targets Nattokinase: An Updated Critical Review on Challenges and Perspectives
Cardiovascular & Hematological Agents in Medicinal Chemistry Cyano Acrylate Polymers in Medical Applications
Recent Patents on Materials Science Hypercoagulability and Nephrotic Syndrome
Current Vascular Pharmacology Takotsubo Cardiomyopathy: What we have Learned in the Last 25 Years? (A Comparative Literature Review)
Current Cardiology Reviews Pulmonary Arterial Hypertension in HIV-infected Patients
Current Hypertension Reviews Respiratory Tract Manifestations of Rheumatic Diseases in Children
Current Respiratory Medicine Reviews Subject Index To Volume 12
Current Pharmaceutical Design Heterogeneity of Synthetic Factor Xa Inhibitors
Current Pharmaceutical Design Impact of Cytochrome P450 2C19*2 and *3 on Clopidogrel Loading Dose in Saudi Patients with Acute Coronary Syndrome
Drug Metabolism Letters Catastrophic Antiphospholipid Syndrome - 20 Years Later
Current Rheumatology Reviews Emerging Indications for Statins: A Pluripotent Family of Agents with Several Potential Applications
Current Pharmaceutical Design Chylothorax
Current Respiratory Medicine Reviews New Substrate Analogue Inhibitors of Factor Xa Containing 4-Amidinobenzylamide as P1 Residue: Part 1
Medicinal Chemistry NOAC in Acute Coronary Syndrome and AF?
Cardiovascular & Hematological Disorders-Drug Targets Synthesis, Anticlotting and Antiplatelet Effects of 1,2,3-Triazoles Derivatives
Medicinal Chemistry Systemic Lupus Erythematosus: Correlation Between Immunodysregulation and Clinical Manifestations
Current Rheumatology Reviews